Selective Modulation of Thyroid Receptor Action
甲状腺受体作用的选择性调节
基本信息
- 批准号:7167744
- 负责人:
- 金额:$ 31.6万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2004
- 资助国家:美国
- 起止时间:2004-01-01 至 2007-12-31
- 项目状态:已结题
- 来源:
- 关键词:AffectAgonistAnimalsAreaArrhythmiaBehaviorBindingBody Weight decreasedCell LineCellsCholesterolClassComplexConditionDNADNA BindingDevelopmentDiseaseDissociationElectrophoretic Mobility Shift AssayElementsEndopeptidasesEquilibriumEventExhibitsGC 1 compoundGene ExpressionGene TargetingGenesGenetic TranscriptionGoalsHeartHeart RateHumanHydrophobic InteractionsHyperthyroidismIn VitroIndividualLifeLigand BindingLigand Binding DomainLigandsLipoprotein (a)Lipoprotein (a-)LiverMediatingMedicalMetabolismModelingMolecular ConformationMolecular ProfilingMutateN-terminalNorthern BlottingNuclear ReceptorsObesityPeptide HydrolasesPeptidesPhage DisplayPharmaceutical PreparationsPharmacologic SubstancePituitary NeoplasmsPlasmaProcessProductionPropertyProstaglandinsProtein IsoformsRattusReceptor ActivationResearchRetinoidsReverse Transcriptase Polymerase Chain ReactionRoentgen RaysStructureTachycardiaTestingThyroid GlandThyroid Hormone ReceptorThyroid HormonesTriglyceridesVitamin Danalogbasecardiovascular disorder riskchromatin immunoprecipitationcofactorcombinatorialconceptdesignhepatoma celllipid disordermigrationneoplastic cellnovelpromoterprototypereceptorreceptor bindingreceptor functionresponsesteroid hormonesuccesstime useuptake
项目摘要
DESCRIPTION (provided by applicant): Nuclear receptors (NRs) regulate numerous medically important processes in humans and include receptors for thyroid (TH) and steroid hormones, vitamin D, retinoids and prostaglandins. Selective modulation of NR function is an emerging concept in NR ligand design. While there is progress, many concepts are poorly understood. Many TH actions would have medical utility in reducing cardiovascular disease risk. TH stimulates metabolism, promotes weight loss, and lowers plasma levels of cholesterol, triglycerides, and lipoprotein (a). However, TH benefits are offset by deleterious influences, including effects on heart that include life-threatening tachycardia and arrhythmia. It is desirable to block TH in hyperthyroidism, but current blockade by inhibiting TH production is slow in onset. Thus, it is important to identify selective TR modulators (STRMs). We used structure-activity profiling and TR X-ray crystal structures for designing: (i) selective TR modulators (STRMs) that preferentially bind the TRbeta-form, and may be prototype drugs for treating obesity and lipid disorders; and (ii) novel TR antagonists and partial agonists. Preliminary studies indicate that these ligands could have further potentially useful selective properties, including differences in cell uptake, activation and suppression of individual promoter elements, and abilities of their activities to be regulated by coactivators and corepressors. In the proposed studies we plan to examine properties of a spectrum of ligands to better understand their activities. We will determine effects of individual STRMs on: (i) TR conformation; (ii) TR interactions with cofactors in cell-free conditions and in cells; (iii) individual TR activation functions; (iv) TR-mediated gene expression at model promoters; and (v) gene expression profiles in intact cells. The information obtained will be integrated to provide profiles for individual and combinatorial features that may be ultimately exploited for rational design of ligands with more desirable profiles than either pure agonists or antagonists. This study will expand our understanding of selective TR modulation in specific and NR action in general.
描述(由申请人提供):核受体(NR)调节人类的许多医学重要过程,包括甲状腺(TH)和类固醇激素、维生素D、类维生素A和肾上腺素的受体。NR功能的选择性调节是NR配体设计中的一个新兴概念。虽然取得了进展,但许多概念仍不为人所知。许多TH行动在降低心血管疾病风险方面具有医疗效用。TH刺激新陈代谢,促进体重减轻,降低胆固醇、甘油三酯和脂蛋白(a)的血浆水平。然而,TH益处被有害影响抵消,包括对心脏的影响,包括危及生命的心动过速和心律失常。在甲状腺功能亢进症中,需要阻断TH,但目前通过抑制TH产生的阻断作用起效缓慢。因此,鉴定选择性TR调节剂(STRM)是重要的。我们使用结构-活性分析和TR X射线晶体结构来设计:(i)选择性TR调节剂(STRM),其优先结合TR β形式,并且可以是用于治疗肥胖和脂质紊乱的原型药物;和(ii)新型TR拮抗剂和部分激动剂。初步研究表明,这些配体可能有进一步的潜在有用的选择性,包括在细胞摄取,激活和抑制个别启动子元件的差异,和他们的活动的能力,以调节辅激活子和辅阻遏物。在拟议的研究中,我们计划检查配体光谱的性质,以更好地了解它们的活动。我们将确定单个STRM对以下方面的影响:(i)TR构象;(ii)无细胞条件下和细胞中TR与辅因子的相互作用;(iii)单个TR激活功能;(iv)模型启动子处TR介导的基因表达;以及(v)完整细胞中的基因表达谱。所获得的信息将被整合,以提供个人和组合的功能,可以最终开发的配体的合理设计更理想的配置文件比纯激动剂或拮抗剂的配置文件。这项研究将扩大我们的理解,选择性TR调制的具体和NR的行动一般。
项目成果
期刊论文数量(2)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
JOHN D BAXTER其他文献
JOHN D BAXTER的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('JOHN D BAXTER', 18)}}的其他基金
STRUCTURAL CHARACTERIZATION OF THE TAF1-TAF7 TFIID SUBCOMPLEX
TAF1-TAF7 TFIID 子复合物的结构表征
- 批准号:
8361716 - 财政年份:2011
- 资助金额:
$ 31.6万 - 项目类别:
相似国自然基金
Agonist-GPR119-Gs复合物的结构生物学研究
- 批准号:32000851
- 批准年份:2020
- 资助金额:24.0 万元
- 项目类别:青年科学基金项目
相似海外基金
S1PR1 agonistによる脳血液関門制御を介した脳梗塞の新規治療法開発
S1PR1激动剂调节血脑屏障治疗脑梗塞新方法的开发
- 批准号:
24K12256 - 财政年份:2024
- 资助金额:
$ 31.6万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
AHR agonistによるSLE皮疹の新たな治療薬の開発
使用 AHR 激动剂开发治疗 SLE 皮疹的新疗法
- 批准号:
24K19176 - 财政年份:2024
- 资助金额:
$ 31.6万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Evaluation of a specific LXR/PPAR agonist for treatment of Alzheimer's disease
特定 LXR/PPAR 激动剂治疗阿尔茨海默病的评估
- 批准号:
10578068 - 财政年份:2023
- 资助金额:
$ 31.6万 - 项目类别:
AUGMENTING THE QUALITY AND DURATION OF THE IMMUNE RESPONSE WITH A NOVEL TLR2 AGONIST-ALUMINUM COMBINATION ADJUVANT
使用新型 TLR2 激动剂-铝组合佐剂增强免疫反应的质量和持续时间
- 批准号:
10933287 - 财政年份:2023
- 资助金额:
$ 31.6万 - 项目类别:
Targeting breast cancer microenvironment with small molecule agonist of relaxin receptor
用松弛素受体小分子激动剂靶向乳腺癌微环境
- 批准号:
10650593 - 财政年份:2023
- 资助金额:
$ 31.6万 - 项目类别:
AMPKa agonist in attenuating CPT1A inhibition and alcoholic chronic pancreatitis
AMPKa 激动剂减轻 CPT1A 抑制和酒精性慢性胰腺炎
- 批准号:
10649275 - 财政年份:2023
- 资助金额:
$ 31.6万 - 项目类别:
Investigating mechanisms underpinning outcomes in people on opioid agonist treatment for OUD: Disentangling sleep and circadian rhythm influences on craving and emotion regulation
研究阿片类激动剂治疗 OUD 患者结果的机制:解开睡眠和昼夜节律对渴望和情绪调节的影响
- 批准号:
10784209 - 财政年份:2023
- 资助金额:
$ 31.6万 - 项目类别:
A randomized double-blind placebo controlled Phase 1 SAD study in male and female healthy volunteers to assess safety, pharmacokinetics, and transient biomarker changes by the ABCA1 agonist CS6253
在男性和女性健康志愿者中进行的一项随机双盲安慰剂对照 1 期 SAD 研究,旨在评估 ABCA1 激动剂 CS6253 的安全性、药代动力学和短暂生物标志物变化
- 批准号:
10734158 - 财政年份:2023
- 资助金额:
$ 31.6万 - 项目类别:
A novel nanobody-based agonist-redirected checkpoint (ARC) molecule, aPD1-Fc-OX40L, for cancer immunotherapy
一种基于纳米抗体的新型激动剂重定向检查点 (ARC) 分子 aPD1-Fc-OX40L,用于癌症免疫治疗
- 批准号:
10580259 - 财政年份:2023
- 资助金额:
$ 31.6万 - 项目类别:
Identification and characterization of a plant growth promoter from wild plants: is this a novel plant hormone agonist?
野生植物中植物生长促进剂的鉴定和表征:这是一种新型植物激素激动剂吗?
- 批准号:
23K05057 - 财政年份:2023
- 资助金额:
$ 31.6万 - 项目类别:
Grant-in-Aid for Scientific Research (C)